Study | Conjunctival bleeding and conjunctivitis | Nasal bleeding | Gingival bleeding |
---|---|---|---|
WHO, [11] | 55.0 % (48.5–61.3 %) |  | 67.4 % (61.4–73.3 %) |
Baron et al., [2] |  | 21.9 % (7.6–36.2 %) | 34.4 % (17.9–50.8 %) |
Sureau, [46] |  | 14.7 % (10.5–19.0 %) | 22.3 % (17.3–27.3 %) |
Bwaka et al., [47] | 42.7 % (33.0–52.8 %) | 1.9 % (0.0–4.6 %) | 12.6 % (6.2–19.0 %) |
Georges et al., [48] | 53.3 % (26.6–78.7 %) | 13.3 % (0.0–30.5 %) | 40.0 % (15.2–64.8 %) |
Khan et al., [49] | 35.7 % (29.2–42.6 %) |  | 22.1 % (16.5–27.8 %) |
Ndambi et al., [50] | 78.3 % (56.3–92.5 %) | 4.3 % (0.0–12.7 %) | 30.4 % (11.6–49.2 %) |
Mupere et al., [51] | 40.0 % (19.1–63.9 %) | 10.0 % (0.0–23.1 %) | 10.0 % (0.0–23.1 %) |
Roddy et al., [52] | 50.0 % (29.9–70.1 %) | 7.7 % (0.0–17.9 %) | 3.8 % (0.0–11.2 %) |
Maganga et al., [53] | 15.8 % (6.0–31.3 %) | 10.5 % (0.8–20.3 %) | 7.9 % (0.0–16.5 %) |
Schieffelin et al., [54] | 25.0 % (13.2–40.3 %) |  |  |
Bah et al., [55] | 10.8 % (3.0–25.4 %) | 5.4 % (0.0–12.7 %) |  |
Dallatomasina et al., [56] | 2.0 % (0.7–4.7 %) |  |  |
WHO Ebola Response Team, [57] | 26.0 % (24.6–27.4 %) | 1.3 % (0.9–1.7 %) | 1.9 % (1.4–2.4 %) |
Yan et al., [58] | 34.3 % (25.4–44.0 %) |  |  |